Trials / Completed
CompletedNCT00263718
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris
Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle and the Gel Vehicle Alone in Psoriasis Vulgaris
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 360 (planned)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to compare the use of calcipotriol plus betamethasone dipropionate gel with betamethasone dipropionate in the gel vehicle, calcipotriol in the gel vehicle and the gel vehicle alone when used in patients with psoriasis vulgaris on the trunk and/or limbs. Patients will be treated once daily for up to 8 weeks. The primary response criterion is the number of patients with controlled disease at week 8.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Calcipotriol plus betamethasone dipropionate (LEO 80185) gel |
Timeline
- Start date
- 2005-12-01
- Completion
- 2006-05-01
- First posted
- 2005-12-09
- Last updated
- 2025-02-24
Locations
5 sites across 5 countries: Canada, Germany, Ireland, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00263718. Inclusion in this directory is not an endorsement.